CARDIOVASCULAR COMPLICATIONS AND ENDOTHELIAL DYSFUNCTION IN PRIMARY VASCULITIS


Cite item

Full Text

Abstract

Russian and foreign data on development of atherosclerosis in patients with primary vasculitis are analysed. The discussion covers the role of risk factors, features of pathogenesis of atherosclerosis in primary vasculitis, diagnostic and therapeutic methods in this disease.

About the authors

L A Strizhakov

I.M. Sechenov First State Medical University

Email: strizhakov76@mail.ru
канд. мед. наук, доц. каф. терапии и профболезней

S V Moiseev

I.M. Sechenov First State Medical University

Email: clinpharm@mtu-net.ru
д-р мед. наук, проф. каф. терапии и профболезней

E N Semenkova

I.M. Sechenov First State Medical University

д-р мед. наук, проф. каф. терапии и профболезней

E I Kuznetsova

I.M. Sechenov First State Medical University

Email: kei1986@mail.ru
клин. ординатор каф. терапии и профболезней

References

  1. Hall F. C., Dalbeth N. Disease modification and cardiovascular risk reduction: two sides of the same coin? Rheumatology 2005; 44 (12): 2—10.
  2. Leuven S. I., Franssen R., Kasteilen J. J. Systemic inflammation as a risk factor for atherosclerosis. Rheumatology 2008; 47: 3—7.
  3. Насонов Е. Л., Насонова В. А. (ред.). Ревматология: Нац. руководство. М.: Гэотар-Медиа; 2008. 647—660.
  4. Дряженкова И. В. Поражение сердечно-сосудистой системы при ревматических болезнях. Кардиология 2005; 11: 98—104.
  5. Шилкина Н. П., Дряженкова И. В. Системные васкулиты и атеросклероз. Тер. арх. 2007; 3: 84—92.
  6. Насонов Е. Л., Баранов А. А., Шилкина Н. П. Васкулиты и васку-лопатии. Ярославль: Верхняя Волга; 1999.
  7. Goodson N. J., Wiles N. J., Lunt M. Mortality in early inflammatory polyarthritis. Cardiovascular mortality is increased in seropositive patients. Arthr. and Rheum. 2002; 46: 2010—2019.
  8. Hetjmancik M. R., Wright J. C., Quint R. et al. The cardiovascular manifestations of systemic lupus erythematosus. Am. Heart J. 1964; 68: 119—130.
  9. Jensen G., Sigurd B. Systemic lupus erythematosus and acute myocardial infarction. Chest 1973; 64: 653—654.
  10. Urowitz M. B., Bookman A. A. M., Koehler B. E. et al. The bimodal mortality pattern of systemic lupus erythematosus. Am. J. Med. 1976; 60: 221—225.
  11. Gladman D. D., Urowitz M. B. Morbidity in systemic lupus erythematosus. J. Rheumatol. 1987; 14 (Suppl. 13): 223—226.
  12. Ward M. M. Premature morbidity from cardiovascular and cerebrovascular diseases in women with systemic lupus erythematosus. Arthr. and Rheum. 1999; 42: 338—346.
  13. Bukley B. H., Roberts W. C. The heart in systemic lupus erythematosus and the changes induced in it by corticosteroid therapy: a study of 36 necropsy patients. Am. J. Med. 1975; 58: 243—264.
  14. Doherty N. E., Siegel R. J. Cardiovascular manifestation of systemic lupus erythematosus. Am. Heart J. 1985; 110: 1257—1265.
  15. Libby P., Ridker P. M., Maseri A. Inflammation and atherosclerosis. Circulation 2002; 105: 1135—1143.
  16. Van Doornum S., King B., Brand C. Mortality rates following a first acute cardiovascular event: a comparison between rheumatoid arthritis patients and the general population. Arthr. and Rheum. 2005; 52: 702.
  17. Churg C. P., Oeser A., Raggi P. Increased coronary-artery atherosclerosis in rheumatoid arthritis: relationship to disease duration and cardiovascular risk factors. Arthr. and Rheum. 2005; 52: 3045—3053.
  18. Solomon D. H., Karlson E. W., Rimm E. B. et al. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 2003; 107: 1303—1307.
  19. Mazer S. P., Rabbani L. E. Evidence for C-reactive protein’s (CRP) role in vascular disease: atherothrombosis, immunoregulation and CRP Thromb. Thrombolys. 2004; 17: 95—105.
  20. Van Oostrom A. J., Van Wijk J., Cabezaz M. C. Lipaemia, inflammation and atherosclerosis: novel opportunities in the understanding and treatment of atherosclerosis. Drugs 2004; 64: 19—41.
  21. Everett B. M., Kurth T., Buring J. E., Ridker P. M. The relative strength of C-reactive protein and lipid levels as determinants of ischemic stroke compared with coronary heart disease in women. J. Am. Coll. Cardiol. 2006; 48 (11): 2235—2242.
  22. Ridker P. M., Rifai N., Pfeffer M. et al. Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction. Circulation 2000; 101: 2149—2153.
  23. Biasucci L. M., Vitelli A., Liuzzo G. et al. Elevated levels of interleukin-6 in unstable angina. Circulation 1996; 94: 874—877.
  24. Shoenfeld Y., Gerli R., Doria A. et al. Accelerated atherosclerosis in autoimmune rheumatic diseases. Circulation 2005; 112: 3337—3347.
  25. Ross R. Athrosclerosis. An inflammatory disease. N. Engl. J. Med. 1999; 340: 115—126.
  26. Qiao J. H., Castelllani L. W., Fishbein M. C., Luis A. J. Immune complex-mediated vasculitis increases coronary artery lipid accumulation in autoimmune-prone MRL mice. Arterioscler. Thromb. 1993; 13: 932—943.
  27. Wick G., Romen M., Amberger A. et al. Atherosclerosis, autoimmunity, and vascular-associated lymphoid tissue. FASEB J. 1997; 11: 1199—1207.
  28. Shoenfeld Y., Sherer Y., Haratz D. Atherosclerosis as an infectious, inflammatory and autoimmune disease. Trends Immunol. 2001; 22: 293—295.
  29. van Leuven S. I., Franssen R., Kastelein J. J. et al. Systemic inflammation as a risk factor for atherothrombosis. Rheumatology 2008; 47 (1): 3—7.
  30. Семенкова Е. Н. Системные васкулиты. М.: Медицина; 1988.
  31. Семенкова Е. Н. Трудности диагностики коронарита при системных васкулитах. Тер. арх. 1994; 66 (5): 50—54.
  32. Schrader M., Hochman J., Bulkley B. The heart in poltarteritis nodosa: A clinicopathologic study. Am. Heart J. 1985; 109: 1353—1359.
  33. Wagner A. D., Feist T., Prondzinsky R. et al. Joint and muscle pain with mononeuritis multiplex, tetraparesis, and myocardial infarction in a previously healthy adult. Ann. Rheum. Dis. 2001; 60: 1003—1006.
  34. Kastner D., Gaffney M., Tak T. Polyarteritis nodosa and myocardial infarction. Can. J. Cardiol. 2000; 16 (4): 515—518.
  35. Rajani R. M., Dalvi B. V., D’Silva S. A. et al. Acute myocardial infarction with normal coronary arteries in a case of polyarteritis nodosa: possible role of coronary artery spasm. Postgrad. Med. J. 1991; 67: 78—80.
  36. Liozon F., Vidal E., Gaches F. et al. Death in Horton disease. Prognostic factors. Rev. Med. Interne 1992; 13 (3): 187—191.
  37. Freire de Carvalho J., Bonfa E., Bezerra M. C., Rodrigues Pereira R.M. High frequency of lipoprotein risk levels for cardiovascular disease in Takayasu arteritis. Clin. Rheumatol. 2009; 28 (7): 801—805.
  38. Seyahi E., Ugurlu S., Cumali R. et al. Atherosclerosis in Takayasu arteritis. Ann. Rheum. Dis. 2006; 65 (9): 1202—1207.
  39. Park K. C., Kim J. H., Yoon S. S., Heo S. H. Takayasu’s disease presenting with atherothrombotic ischaemic stroke. Neurol. Sci. 2008; 29 (5): 363—366.
  40. Filer A., Nicholls D., Corston R. et al. Takayasu arteritis and atherosclerosis: illustrating the consequences of endothelial damage. J. Rheumatol. 2001; 28 (12): 2752—2753.
  41. Faurschou M., Mellemkjaer L., Sorensen I. et al. Increased morbidity from ischemic heart disease in patients with Wegener’s granulomatosis. Arthr. and Rheum. 2009; 60 (4): 1187—1192.
  42. Raza K., Thambyrajah J., Townsend J. N. et al. Suppression of inflammation in primary systemic vasculitis restores vascular endothelial function: Lessons for atherosclerotic disease? Circulation 2000; 102: 1470.
  43. de Leeuw K., Sanders J. S., Stegeman C. et al. Accelerated atherosclerosis in patients with Wegener’s granulomatosis. Ann. Rheum. Dis. 2005; 64 (5): 753—759.
  44. Nienhuis H. L. A., De Leeuw K., Smit A. J. et al. Enhanced endothelium-dependent microvascular responses in patients with Wegener’s granulomatosis. J. Rheumatol. 2007; 34 (9): 1875—1881.
  45. Bacon P. A., Moots R. J. I. Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. Quart. J. Med. 1994; 87: 671—678.
  46. Booth A. D., Jayne D. R. W., Kharbanda R. K. et al. Infliximab improves endothelial dysfunction in systemic vasculitis. Circulation 2004; 109: 1718—1723.
  47. Swets B. P., Brouder A. J., Tervaert J. W. Patients with systemic vasculitis have increased levels of autoantibodies against oxidized LDL. Clin. Exp. Immunol. 2001; 124 (1): 163—167.
  48. Chironi G., Pagnoux C., Simon A. et al. Increased prevalence of subclinical atherosclerosis in patients with small-vessel vasculitis. Heart 2007; 93: 96—99.
  49. Giles J., Post W., Blumenthal R. et al. Therapy insight: managing cardiovascular risk in patients with rheumatoid arthritis. Nature Clin. Pract. Rheumatol. 2006; 2 (6): 320—329.
  50. Choi H. K., Hernan M. A., Seeger J. D. Methotrexate and mortality in patints with rheumatoid arthritis: a prospective study. Lancet 2002; 359: 1173—1177.
  51. Jacobsson L. T., Askling J., Rantapaa-Dahlvist S. Anti-TNF therapy and risk of death up to 8 years after treatment start. Results from the Swedish biologics register (ARTIS). Ann. Rheum. Dis. 2008; 67: 183.
  52. Gazi I. F., Boumpas D. T., Mikhalidis D. et al. Clustering of cardiovascular risk factors in rheumatoid arthritis: the rationale for using statins. Clin. Exp. Rheumatol. 2007; 25: 102—111.
  53. Jury E. C., Ehrenstein M. R. Statins: immunomodulators for autoimmune rheumatic disease? Lupus 2005; 14 (3): 192—196.
  54. Bijl M. Endothelial activation, endothelial dysfunction and premature atherosclerosis in systemic autoimmune diseases. Neth. J. Med.l 2003; 61 (9): 273—277.
  55. Bisoendial R., Stroes E., Kastelein J., Tak P. Tageting cardiovascular risk in rheumatoid arthritis: dual role for statins. Nature Rev. Rheumatol. 2010; 6 (3): 157—164.
  56. Marz W., Koenig W. HMG-CoA reductase inhibition: Anti-inflammatory effects beyond lipid lowering? J. Cardiovasc. Risk 2003; 10 (3): 169—179.

Copyright (c) 2012 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies